Association of regional white matter hyperintensity volumes with cognitive dysfunction and vascular risk factors in patients with amnestic mild cognitive impairment

Kentaro Hirao, Fumio Yamashita, Shu Sakurai, Akito Tsugawa, Rieko Haime, Raita Fukasawa, Tomohiko Sato, Hidekazu Kanetaka, Takahiko Umahara, Hirofumi Sakurai, Haruo Hanyu and Soichiro Shimizu

1Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan
2Department of Ultrahigh Field MRI, Institute for Biomedical Sciences, Iwate Medical University, Iwate, Japan

Correspondence
Kentaro Hirao MD, Department of Geriatric Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
Email: kentaroh@tokyo-med.ac.jp

Aim: White matter hyperintensities (WMH) obtained by magnetic resonance imaging (MRI) have been reported to promote neurodegeneration and cognitive decline in patients with mild cognitive impairment (MCI). However, little is known about the association between regional WMH (rWMH) and cognitive dysfunction in MCI. We hence investigated the associations between rWMH volumes and cognitive dysfunction in MCI.

Methods: Thirty-eight subjects with amnestic MCI were analysed. The volumes of periventricular hyperintensities (PVH) and deep WMH (DWMH) were measured on a T2-FLAIR MRI using a 3D-slicer, and regional PVH and DWMH (rPVH and rDWMH) volumes were calculated. The associations of rPVH and rDWMH volumes with cognition and blood levels of various molecules were investigated. Furthermore, rPVH and rDWMH volumes were compared between MCI with vascular risk factors, such as hypertension, diabetes mellitus (DM), and dyslipidemia, and those without these risk factors.

Results: rPVH volume (bilateral cornu frontale, pars parietalis, and cornu occipitale) positively correlated with Trail Making Test-A/B scores and CysC level, whereas rDWMH volume did not correlate with any of the items. rPVH volumes (right cornu frontale, bilateral pars parietalis and cornu occipitale, and right pars temporalis) and rDWMH volumes (left frontal and parietal lobes) were significantly larger in MCI patients with DM than in those without.

Conclusions: PVH volumes (bilateral areas of cornu frontale, pars parietalis, and cornu occipitale) were closely associated with attention and executive dysfunction. Serum CysC level and DM were associated with WMH volume, suggesting that CysC level and DM might be important markers for determining treatment strategies for white matter abnormalities in MCI. Geriatr Gerontol Int 2021; 

Keywords: cystatin C, deep white matter hyperintensities, mild cognitive impairment, periventricular hyperintensities, regional white matter hyperintensities.

Introduction

The contribution of white matter abnormalities to clinical symptoms, such as cognitive dysfunction and geriatric depression, and the pathogenesis of Alzheimer’s disease (AD) has been increasingly recognized.1-3 White matter hyperintensities (WMH) displayed by magnetic resonance imaging (MRI) have been shown to be a risk factor for the conversion from mild cognitive impairment (MCI) to AD. Several recent studies have reported associations between WMH, such as of the periventricular and parietal white matter regions, and the risk of the future development of AD, although MCI is a heterogeneous disorder with a variety of clinical outcomes (amnestic and nonamnestic MCI, etc.).4,5 However, most of these studies have assessed WMH by visual rating, which is not very precise. We recently reported the association of periventricular hyperintensity (PVH) volume with attention and executive dysfunction in amnestic MCI patients.6 However, we did not assess the associations between WMH in specific locations and cognitive dysfunction. In the present study, we hence calculated regional WMH (rWMH) volumes using a parcellated template, and investigated the association between rWMH volumes and cognitive dysfunction, blood levels of various molecules, and the presence of vascular risk factors, such as hypertension (HT), diabetes mellitus (DM), and dyslipidemia (DL), in amnestic MCI patients.

Materials and methods

Subjects

Outpatients (aged > 60 years and <90 years) who were enrolled at the memory clinic or outpatient clinic of Tokyo Medical University were prospectively recruited between 2015 and 2018. Written informed consent was obtained from all subjects before the study.

© 2021 The Authors. Geriatrics & Gerontology International published by John Wiley & Sons Australia, Ltd on behalf of Japan Geriatrics Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
The study design was approved by the ethics review board of Tokyo Medical University. Data from 38 subjects with amnestic MCI and from 10 normal control (NC) subjects, who were spouses of the MCI subjects or who were being followed at the outpatient clinic but had no memory complaints, were medically stable, and had Mini Mental State Examination (MMSE) scores of 28 and above, were analysed. All patients underwent detailed general physical, neurological, and psychiatric examinations, and extensive laboratory tests, including MRI and single-photon emission computed tomography (SPECT). SPECT images were analysed using Neurological Statistical Image Analysis software, which has three-dimensional stereotactic surface projections developed by Minoshima et al. for evaluating the spatial distribution of abnormal perfusion, to exclude other potential causes of dementia, including dementia with Lewy bodies and frontotemporal lobar degeneration, etc. A reduction in regional cerebral blood flow (rCBF) of the parietotemporal association cortex on SPECT has been recognized as a diagnostic pattern of prodromal AD. The subjects were diagnosed as having MCI due to AD according to the National Institute on Aging–Alzheimer’s Association criteria, and their MMSE scores were 24 or above. Subjects were excluded from the study if they did not show any reduction in rCBF in the parietotemporal association areas. Subjects were also excluded if they had territorial or cortical infarctions, or if they showed severe white matter abnormalities in which both PVH and DWMH were grade 3 on the Fazekas scale. Cognitive functions and depressive symptoms were assessed by various neuropsychological tests, such as MMSE, Frontal Assessment Battery (FAB), Trail Making Test (TMT)-A/B, Wechsler Memory Scale-Revised-Logical Memory I, category verbal fluency, and Geriatric Depression Scale (GDS-15).

Levels of serum CysC, 25-hydroxyvitamin D, and homocysteine were measured using colloidal gold agglutination, radioimmunocassay, and high-performance liquid chromatography, respectively. The levels of other cerebrovascular risk factors, including total cholesterol, low-density lipoprotein cholesterol, glucose, hemoglobin A1c, vitamin B12, blood urea nitrogen, creatinine, estimated glomerular filtration rate, aspartate transaminase, and alanine aminotransferase were also measured.

**Magnetic resonance imaging and volumetric analysis**

Brain MRI scans (3D-T1 and T2 fluid-attenuated inversion recovery [FLAIR] imaging) were performed using a 1.5-tesla scanner (Magnetom; Siemens Medical Systems, Erlangen, Germany). FLAIR sequences were obtained using the following parameters: TR, 9000 ms; TE, 104 ms; TI, 2500 ms; slice thickness, 4.0 mm; and gap, 0.0 mm. For quantitative analysis of WMH volumes, FLAIR images were registered. WMH was defined as the presence of hyperintensity in the white matter area. PVH and DWMH lesions were outlined by a neurologist, using the semiautomated freeware 3D-slicer, which is a freely available, open-source software package for the visualization, registration, segmentation, and quantification of medical data (http://www.slicer.org). Furthermore, intracranial volumes (ICVs) were calculated on 3D-T1 using the Voxel-based morphometry, which was implemented in Statistical Parametric Mapping (SPM8, Welcome Institute of Neurology, University College London, UK), and the ratios (%) of PVH and DWMH volumes to ICV were used for rating white matter abnormalities. For assessing regional PVH and DWMH (rPVH and rDWMH), rPVH and rDWMH volumes in each periventricular parcellated region within bilateral areas of the corona frontale, pars parietalis, cornu occipitale, and pars temporalis/lobar; and within bilateral areas of the frontal, parietal, occipital, and temporal lobes were calculated. These regions were manually parcellated in a template image, which was used in automated WMH extraction analysis. The parcellated regions were mapped onto individual brains using the nonlinear warping parameter calculated from the automated process. Correlations between rPVH and rDWMH volumes to ICV ratio (%) and cognitive function, and blood levels of various molecules, r were investigated. Furthermore, rPVH and rDWMH volumes were compared between MCI patients with vascular risk factors, such as HT, DM, and DL, and MCI patients without these risk factors.

**Statistical analysis**

Demographic and laboratory data were calculated as means ± SD. Statistical analyses (the Student t-test, Pearson test, linear multiple regression analysis, and analysis of covariance [ANCOVA]) were performed using SPSS 26.0 software.

**Results**

A summary of the comparisons of subject characteristics is shown in Table 1. There were significant differences between the MCI group and the NC group with regard to scores on neuropsychological tests, such as MMSE, FAB, TMT-B, and GDS-15. Table 2 shows a comparison of total/regional PVH and DWMH volumes with ICV ratio between the MCI group and the NC group. In

---

### Table 1  Demographic, clinical, and blood biochemistry data of MCI and NC subjects

|                | MCI (n = 38) | NC (n = 10) |
|----------------|-------------|-------------|
| Sex (M/F)      | 13/25       | 5/5         |
| Age (years)    | 77.4 ± 5.6  | 76.5 ± 6.2  |
| Education (years) | 13.4 ± 2.3  | 14.4 ± 1.6  |
| MMSE           | 27.3 ± 1.6  | 28.7 ± 0.9  |
| FAB            | 13.0 ± 2.2* | 14.9 ± 2.0  |
| TMT-A (seconds)| 52.7 ± 20.8 | 42.2 ± 12.6 |
| TMT-B (seconds)| 156.9 ± 80.8| 102.5 ± 39.6|
| WMS-R-Logical Memory (immediate) | 13.6 ± 6.7 | 15.5 ± 5.9 |
| VF (category)  | 14.5 ± 3.4  | 15.9 ± 3.4  |
| GDS-15         | 3.8 ± 3.1*  | 1.7 ± 1.4   |
| HbA1c (%)      | 5.9 ± 0.4   | 6.1 ± 0.5   |
| T-Chol (mg/dL) | 205.0 ± 33.6| 187.2 ± 17.6|
| LDL-Chol (mg/dL)| 131.3 ± 26.0| 103.4 ± 17.6|
| eGFR (mL/min/1.73 m²) | 66.2 ± 13.4 | 67.5 ± 18.9 |
| Cystatin C (mg/L) | 1.0 ± 0.2 | 1.1 ± 0.3 |
| 25(OH) VitD (ng/mL) | 25.0 ± 11.9 | 19.9 ± 6.1 |
| Homocysteine (unomol/mL) | 10.5 ± 3.5 | 9.4 ± 2.8 |
| Systolic blood pressure (mmHg) | 133.7 ± 17.4 | 132.2 ± 13.9 |
| Diastolic blood pressure (mmHg) | 73.7 ± 13.6 | 74.8 ± 11.1 |
| Hypertension, n (%) | 21 (55) | 2 (20) |
| Diabetes mellitus, n (%) | 7 (18) | 3 (30) |
| Dyslipidemia, n (%) | 20 (53) | 4 (40) |
| Coronary artery disease, n (%) | 3 (8) | 1 (10) |

*P < 0.05 between MCI and NC.

25(OH) VitD, 25-hydroxyvitamin D; eGFR, estimated glomerular filtration rate; FAB, Frontal Assessment Battery; GDS, Geriatric Depression Scale; HbA1c, hemoglobin A1c; LDL-Chol, low-density lipoprotein cholesterol; MCI, mild cognitive impairment; MMSE, Mini Mental State Examination; NC, normal control; T-Chol, total cholesterol; TMT, Trail Making Test; VF, verbal fluency; WMS-R, Wechsler Memory Scale-Revised.
Association of rWMH with cognition

**Table 2** Comparison of ratios of total WMH and regional WMH volume to ICV between MCI and NC patients

| Location of WMH | MCI (n = 38) | NC (n = 10) |
|-----------------|--------------|-------------|
| WMH volume to ICV ratio (%) | WMH volume to ICV ratio (%) |
| Total PVH | 0.70 ± 0.60 | 0.45 ± 0.46 |
| Total DWMH | 0.30 ± 0.70 | 0.20 ± 0.37 |
| L. periventricular cornu frontale | 1.24 ±10^-1 ± 1.11 ±10^-1 | 0.85 ±10^-1 ± 0.94 ±10^-1 |
| R. periventricular cornu frontale | 1.31 ±10^-1 ± 1.14 ±10^-1 | 0.77 ±10^-1 ± 0.85 ±10^-1 |
| L. periventricular pars parietalis | 2.14 ±10^-1 ± 2.15 ±10^-1 | 1.34 ±10^-1 ± 1.83 ±10^-1 |
| R. periventricular pars parietalis | 2.16 ±10^-1 ± 2.43 ±10^-1 | 1.35 ±10^-1 ± 1.70 ±10^-1 |
| L. periventricular cornu occipitale | 1.29 ±10^-1 ± 1.66 ±10^-1 | 0.79 ±10^-1 ± 1.44 ±10^-1 |
| R. periventricular cornu occipitale | 1.34 ±10^-1 ± 1.74 ±10^-1 | 0.91 ±10^-1 ± 1.48 ±10^-1 |
| L. periventricular pars temporalis | 6.66 ±10^-3 ± 0.11 ±10^-1 | 2.84 ±10^-3 ± 5.15 ±10^-3 |
| R. periventricular pars temporalis | 5.99 ±10^-3 ± 0.11 ±10^-1 | 4.66 ±10^-3 ± 8.56 ±10^-3 |
| L. frontal lobe | 2.67 ±10^-2 ± 5.02 ±10^-2 | 1.58 ±10^-2 ± 3.09 ±10^-2 |
| R. frontal lobe | 2.73 ±10^-2 ± 4.87 ±10^-2 | 2.25 ±10^-2 ± 3.30 ±10^-2 |
| L. temporal lobe | 6.12 ±10^-4 ± 3.40 ±10^-3 | 7.34 ±10^-5 ± 2.32 ±10^-4 |
| R. temporal lobe | 9.49 ±10^-4 ± 3.71 ±10^-3 | 9.54 ±10^-5 ± 3.02 ±10^-4 |
| L. parietal lobe | 7.10 ±10^-3 ± 1.98 ±10^-2 | 1.38 ±10^-3 ± 2.17 ±10^-3 |
| R. parietal lobe | 7.69 ±10^-3 ± 2.30 ±10^-2 | 1.11 ±10^-3 ± 1.49 ±10^-3 |
| L. occipital lobe | 4.23 ±10^-5 ± 1.82 ±10^-4 | <1.0 ±10^-9 |
| R. occipital lobe | 1.78 ±10^-4 ± 0.77 ±10^-4 | <1.0 ±10^-9 |

**DWMH**, deep white matter hyperintensities; **ICV**, intracranial volume; **L**, left; **MCI**, mild cognitive impairment; **NC**, normal control; **PVH**, periventricular hyperintensities; **R**, right; **WMH**, white matter hyperintensities.

**Table 3** Measurements associated with ratios of regional WMH volume to ICV in MCI patients

| Measurements | L. cornu frontale vol. | R. cornu frontale vol. | L. pars parietalis vol. | R. pars parietalis vol. | L. cornu occipitale vol. | R. cornu occipitale vol. |
|--------------|------------------------|-----------------------|------------------------|------------------------|------------------------|------------------------|
| Coefficient/P | 0.37/0.03* | 0.43/0.01* | 0.42/0.01* | 0.42/0.01* | 0.38/0.05* | 0.41/0.02* |
| TMT-A | 0.16/0.37 | 0.19/0.28 | 0.35/0.04* | 0.32/0.04* | 0.35/0.04* | 0.35/0.04* |
| Cystatin C | 0.40/0.01* | 0.36/0.03* | 0.33/0.04* | 0.24/0.16 | 0.32/0.05* | 0.29/0.07 |

*P < 0.05, significant correlation with ratio of regional WMH volume to ICV.

**ICV**, intracranial volume; **L**, left; **MCI**, mild cognitive impairment; **R**, right; **TMT**, Trail Making Test; **WMH**, white matter hyperintensities.

Table 2, the ratio of PVH and DWMH volumes to ICV in every region is greater in the MCI group than in the NC group, but there are no statistically significant differences. Table 3 shows that the ratio of the rPVH volume (bilateral areas of the cornu frontale, pars parietalis, and cornu occipitale) to ICV is significantly correlated with only TMT-A/B scores and CysC level by Pearson analysis. Although the results are not shown, none of the rDWMH volumes are correlated with any of the items. Table 4 shows the correlations between rPVH and rDWMH volume ratios and the blood levels of various molecules, calculated by multiple linear regression analysis. rPVH volume (bilateral cornu frontale and left cornu occipitale) and rDWMH volume (left parietal lobe) were found to correlate positively with CysC level. Table 5 shows a comparison of the ratios of total and regional PVH and DWMH volumes to ICV between MCI patients with each vascular risk factor and those without, after adjusting for age and the presence of other vascular risk factors, i.e., HT, DM, and DL, using ANCOVA. rPVH volumes (right cornu frontale, bilateral pars parietalis and cornu occipitale, and right pars temporalis) and rDWMH volumes (left frontal and parietal lobes) were significantly larger in MCI patients with DM than in those without DM, but the other risk factors showed no effect.

**Discussion**

In this study, we found that rPVH and rDWMH volumes in the MCI group were not statistically significantly different from those of the NC group, although every rPVH and rDWMH volume in the MCI group was greater than that of the NC group. The association between cerebrovascular disease and AD has been reported in many recent studies, including those in which autopsies were performed.3,13 The present study is an extension of our previous study, in which we showed the association between whole PVH volume and frontal lobe dysfunction in patients with amnestic MCI, by demonstrating the association of rWMH volumes with cognitive dysfunction and vascular risk factors.8 We found a significant positive correlation between rPVH volumes (bilateral areas of the cornu frontale, pars parietalis and cornu occipitale) and TMT-A/B scores and CysC level, whereas rDWMH volumes did not correlate with any of the items. The association of rPVH volumes with attention and executive dysfunction in the present study was consistent with the results of our previous study on whole PVH and DWMH volumes.8 Therefore, we believe that the present results demonstrate more clearly that attention and executive dysfunction are associated more closely with PVH volume.
| Dependent variable | HbA1c | T-Cho | LDL-Cho | eGFR | Cystatin C | 25(OH)VitD | Homocysteine |
|--------------------|-------|-------|---------|------|------------|------------|--------------|
|                    | Coef  | P     | Coef    | P    | Coef       | Coef       | Coef         |
| PVH vol. ratio (L. periventricular cornu frontale) | 0.130/0.392 | -0.665/0.029* | 0.322/0.262 | -0.064/0.737 | 0.516/0.039* | 0.184/0.240 | -0.084/0.691 |
| PVH vol. ratio (R. periventricular cornu frontale) | 0.241/0.088 | -0.619/0.026* | 0.158/0.545 | -0.179/0.311 | 0.456/0.046* | 0.141/0.321 | -0.081/0.674 |
| PVH vol. ratio (L. periventricular pars parietalis) | 0.053/0.725 | -0.480/0.106 | -0.076/0.984 | -0.345/0.078 | 0.446/0.071 | -0.116/0.452 | -0.182/0.389 |
| PVH vol. ratio (R. periventricular pars parietalis) | 0.111/0.471 | -0.605/0.048* | 0.163/0.572 | -0.449/0.027* | 0.295/0.233 | -0.044/0.780 | -0.167/0.436 |
| PVH vol. ratio (L. periventricular cornu occipitale) | 0.057/0.690 | -0.410/0.146 | -0.077/0.774 | -0.530/0.007** | 0.349/0.135 | -0.171/0.249 | -0.207/0.305 |
| PVH vol. ratio (R. periventricular cornu occipitale) | -0.120/0.463 | -0.572/0.076 | 0.193/0.529 | -0.165/0.441 | 0.405/0.127 | -0.190/0.259 | -0.003/0.991 |
| PVH vol. ratio (L. periventricular pars temporalis) | 0.265/0.088 | -0.863/0.006* | 0.731/0.015* | -0.264/0.178 | -0.154/0.526 | 0.121/0.440 | 0.477/0.081* |
| PVH vol. ratio (R. periventricular pars temporalis) | 0.222/0.153 | -0.308/0.301 | -0.039/0.891 | -0.285/0.150 | 0.353/0.156 | 0.316/0.051 | -0.384/0.080 |
| DWMH vol. ratio (L. frontal lobe) | 0.311/0.066 | -0.499/0.124 | 0.145/0.639 | -0.393/0.068 | -0.036/0.891 | 0.213/0.214 | 0.009/0.969 |
| DWMH vol. ratio (R. frontal lobe) | -0.095/0.599 | -0.600/0.094 | 0.575/0.099 | 0.073/0.752 | -0.320/0.273 | 0.166/0.373 | 0.499/0.056 |
| DWMH vol. ratio (L. temporal lobe) | -0.122/0.487 | -0.584/0.095 | 0.557/0.103 | 0.094/0.675 | -0.295/0.304 | 0.283/0.127 | 0.485/0.057 |
| DWMH vol. ratio (R. temporal lobe) | 0.071/0.645 | -0.247/0.407 | -0.049/0.866 | -0.119/0.544 | 0.693/0.008** | 0.218/0.174 | -0.496/0.027* |
| DWMH vol. ratio (L. parietal lobe) | 0.208/0.247 | -0.010/0.975 | -0.366/0.268 | -0.414/0.066 | 0.101/0.716 | -0.020/0.912 | -0.281/0.252 |
| DWMH vol. ratio (R. parietal lobe) | 0.050/0.797 | -0.110/0.769 | 0.157/0.708 | -0.319/0.202 | -0.212/0.496 | -0.111/0.579 | -0.045/0.668 |
| DWMH vol. ratio (L. occipital lobe) | 0.107/0.588 | 0.320/0.401 | -0.352/0.077 | -0.196/0.434 | -0.211/0.504 | -0.165/0.415 | 0.129/0.069 |
| DWMH vol. ratio (R. occipital lobe) | 0.265/0.088 | -0.863/0.006* | 0.731/0.015* | -0.264/0.178 | -0.154/0.526 | 0.121/0.440 | 0.477/0.081* |

*P < 0.05, significant correlation with blood level of the molecule.

**P < 0.01, significant correlation with blood level of the molecule.

25(OH)VitD, 25-hydroxyvitamin D; DWMH, deep white matter hyperintensities; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; ICV, intracranial volume; L, left; LDL-Cho, low-density lipoprotein cholesterol; MCI, mild cognitive impairment; PVH, periventricular hyperintensities; R, right; T-Cho, total cholesterol.
| Ratio of total or regional WMH vol. to ICV (%) | HT (+) (n = 21) | HT (-) (n = 17) | DM (+) (n = 7) | DM (-) (n = 31) | DL (+) (n = 20) | DL (-) (n = 18) |
|---------------------------------------------|-----------------|-----------------|----------------|-----------------|-----------------|-----------------|
| Total PVH vol. ratio                        | 0.80 ± 0.12     | 0.57 ± 0.14     | 1.05 ± 0.22    | 0.62 ± 0.10     | 0.61 ± 0.13     | 0.80 ± 0.13     |
| Total DWMH vol. ratio                       | 0.34 ± 0.15     | 0.35 ± 0.17     | 0.94 ± 0.26    | 0.21 ± 0.12     | 0.28 ± 0.15     | 0.42 ± 0.16     |
| PVH vol. ratio (L. periventricular corneum frontale) | 1.41 × 10⁻¹ ± 0.25 × 10⁻¹ | 1.03 × 10⁻¹ ± 0.28 × 10⁻¹ | 1.73 × 10⁻¹ ± 0.43 × 10⁻¹ | 1.13 × 10⁻¹ ± 0.20 × 10⁻¹ | 1.26 × 10⁻¹ ± 0.25 × 10⁻¹ | 1.22 × 10⁻¹ ± 0.27 × 10⁻¹ |
| PVH vol. ratio (R. periventricular corneum frontale) | 1.46 × 10⁻¹ ± 0.25 × 10⁻¹ | 1.13 × 10⁻¹ ± 0.28 × 10⁻¹ | 2.19 × 10⁻¹ ± 0.43 × 10⁻¹ | 1.11 × 10⁻¹ ± 0.20 × 10⁻¹ | 1.27 × 10⁻¹ ± 0.25 × 10⁻¹ | 1.35 × 10⁻¹ ± 0.27 × 10⁻¹ |
| PVH vol. ratio (L. periventricular pars parietalis) | 2.28 × 10⁻¹ ± 0.45 × 10⁻¹ | 1.98 × 10⁻¹ ± 0.51 × 10⁻¹ | 3.71 × 10⁻¹ ± 0.79 × 10⁻¹ | 1.79 × 10⁻¹ ± 0.37 × 10⁻¹ | 1.79 × 10⁻¹ ± 0.46 × 10⁻¹ | 2.53 × 10⁻¹ ± 0.49 × 10⁻¹ |
| PVH vol. ratio (R. periventricular pars parietalis) | 2.43 × 10⁻¹ ± 0.49 × 10⁻¹ | 1.82 × 10⁻¹ ± 0.55 × 10⁻¹ | 4.54 × 10⁻¹ ± 0.85 × 10⁻¹ | 1.62 × 10⁻¹ ± 0.40 × 10⁻¹ | 1.72 × 10⁻¹ ± 0.50 × 10⁻¹ | 2.64 × 10⁻¹ ± 0.53 × 10⁻¹ |
| PVH vol. ratio (L. periventricular corneum occipitale) | 1.32 × 10⁻¹ ± 0.34 × 10⁻¹ | 1.25 × 10⁻¹ ± 0.38 × 10⁻¹ | 2.65 × 10⁻¹ ± 0.59 × 10⁻¹ | 0.98 × 10⁻¹ ± 0.27 × 10⁻¹ | 0.92 × 10⁻¹ ± 0.35 × 10⁻¹ | 1.69 × 10⁻¹ ± 0.36 × 10⁻¹ |
| PVH vol. ratio (R. periventricular corneum occipitale) | 1.55 × 10⁻¹ ± 0.36 × 10⁻¹ | 1.09 × 10⁻¹ ± 0.40 × 10⁻¹ | 2.86 × 10⁻¹ ± 0.62 × 10⁻¹ | 1.00 × 10⁻¹ ± 0.29 × 10⁻¹ | 1.03 × 10⁻¹ ± 0.37 × 10⁻¹ | 1.69 × 10⁻¹ ± 0.39 × 10⁻¹ |
| PVH vol. ratio (L. periventricular pars temporals) | 7.0 × 10⁻³ ± 2.0 × 10⁻³ | 6.0 × 10⁻³ ± 3.0 × 10⁻³ | 1.4 × 10⁻² ± 0.4 × 10⁻² | 0.5 × 10⁻² ± 0.2 × 10⁻² | 6.0 × 10⁻³ ± 2.0 × 10⁻³ | 8.0 × 10⁻³ ± 3.0 × 10⁻³ |
| PVH vol. ratio (R. periventricular pars temporals) | 7.0 × 10⁻³ ± 2.0 × 10⁻³ | 4.0 × 10⁻³ ± 2.0 × 10⁻³ | 1.6 × 10⁻² ± 0.4 × 10⁻² | 0.4 × 10⁻² ± 0.2 × 10⁻² | 5.0 × 10⁻³ ± 2.0 × 10⁻³ | 7.0 × 10⁻³ ± 2.0 × 10⁻² |
| DWMH vol. ratio (L. frontal lobe)            | 2.8 × 10⁻² ± 1.1 × 10⁻² | 2.5 × 10⁻² ± 1.2 × 10⁻² | 6.2 × 10⁻² ± 1.9 × 10⁻² | 1.9 × 10⁻² ± 0.9 × 10⁻² | 2.9 × 10⁻² ± 1.1 × 10⁻² | 2.4 × 10⁻² ± 1.2 × 10⁻² |
| DWMH vol. ratio (R. frontal lobe)            | 3.2 × 10⁻² ± 1.1 × 10⁻² | 2.2 × 10⁻² ± 1.2 × 10⁻² | 5.1 × 10⁻² ± 1.9 × 10⁻² | 2.2 × 10⁻² ± 0.9 × 10⁻² | 2.8 × 10⁻² ± 1.1 × 10⁻² | 2.7 × 10⁻² ± 1.2 × 10⁻² |
| DWMH vol. ratio (L. temporal lobe)           | 1.0 × 10⁻³ ± 1.0 × 10⁻³ | 8.59 × 10⁻⁵ ± 1.0 × 10⁻³ | 1.0 × 10⁻³ ± 1.0 × 10⁻³ | 1.0 × 10⁻³ ± 1.0 × 10⁻³ | <1.0 × 10⁻⁶ ± 0.001 | 0.001 ± 0.001 |
| DWMH vol. ratio (R. temporal lobe)           | 2.0 × 10⁻³ ± 1.0 × 10⁻³ | 0.00 ± 1.0 × 10⁻³ | 1.0 × 10⁻³ ± 1.0 × 10⁻³ | 1.0 × 10⁻³ ± 1.0 × 10⁻³ | <1.0 × 10⁻⁶ ± 0.001 | 0.002 ± 0.001 |
| DWMH vol. ratio (L. parietal lobe)           | 6.0 × 10⁻³ ± 4.0 × 10⁻³ | 9.0 × 10⁻³ ± 5.0 × 10⁻³ | 2.2 × 10⁻² ± 0.8 × 10⁻² | 0.4 × 10⁻² ± 0.4 × 10⁻² | 6.0 × 10⁻³ ± 4.0 × 10⁻³ | 9.0 × 10⁻³ ± 5.0 × 10⁻³ |
| DWMH vol. ratio (R. parietal lobe)           | 8.0 × 10⁻³ ± 5.0 × 10⁻³ | 8.0 × 10⁻³ ± 6.0 × 10⁻³ | 2.1 × 10⁻² ± 0.9 × 10⁻² | 0.5 × 10⁻² ± 0.4 × 10⁻² | 6.0 × 10⁻³ ± 5.0 × 10⁻³ | 1.0 × 10⁻² ± 6.0 × 10⁻³ |

(Continues)
Table 5  Continued

| Ratio of total or regional WMH vol. to ICV (%) | HT (+) (n = 21) | HT (-) (n = 17) | DM (+) (n = 7) | DM (-) (n = 31) | DL (+) (n = 20) | DL (-) (n = 18) |
|---------------------------------------------|-----------------|-----------------|----------------|-----------------|-----------------|-----------------|
| DWMH vol. ratio (L. occipital lobe) | 8.28 *10^{-5} ± 0.00 | 7.59 *10^{-6} ± 0.00 | 7.54 *10^{-6} ± 0.00 | 5.02 *10^{-5} ± 0.00 | 3.51 *10^{-5} ± 0.00 | 5.04 *10^{-5} ± 0.00 |
| DWMH vol. ratio (R. occipital lobe) | <1.00 *10^{-6} ± 0.00 | 4.48 *10^{-5} ± 0.00 | 6.86 *10^{-6} ± 0.00 | <1.00 *10^{-6} ± 0.00 | <1.00 *10^{-6} ± 0.00 | <1.00 *10^{-6} ± 0.00 |

*p < 0.05, significant difference between WMH volume to ICV ratio in MCI patients with DM and in those without DM. **p < 0.01, significant difference between WMH volume to ICV ratio in MCI patients with DM and in those without DM.

Values are shown as the adjusted average volume ± standard error. Adjusted covariates: age and the presence of other vascular risk factors, i.e., HT, DM, and DL.

DM, diabetes mellitus; DL, dyslipidemia; DWMH, deep white matter hyperintensities; HT, hypertension; ICV, intracranial volume; L, left; MCI, mild cognitive impairment; PVH, periventricular hyperintensities; R, right.
might be useful markers for determining treatment strategies for white matter abnormalities in amnestic MCI patients.

Acknowledgements

This study was supported by JSPS KAKENHI (grant no. JP17K09327). We would like to thank H. Hirose and K. Sasaki of the Department of Radiology of Tokyo Medical University Hospital for their support and technical assistance, and N. Fukushima of the Department of Preventive Medicine and Public Health of Tokyo Medical University for providing assistance with the statistical analysis. We are also grateful to the editors of the Department of International Medical Communications at Tokyo Medical University for reviewing the manuscript.

Disclosure statement

The authors have no conflicts of interest to declare regarding this study.

References

1 Birdsell AC, Kosik KL, Jonatins EM et al. Regional white matter hyperintensities: aging, Alzheimer’s disease risk, and cognitive function. Neurobiol Aging 2014; 35: 769–776.
2 Pantoni L, Fiorini F, Poggesi A. Impact of cerebral white matter changes on functionality in older adults: an overview of the LADIS study results and future directions. Geriatr Gerontol Int 2015; 15(Suppl 1):10–16.
3 McAleese KE, Firbank M, Dey M et al. Cortical tau load is associated with white matter hyperintensities. Acta Neuropathol Commun 2015; 3: 60.
4 van Straaten EC, Harvey D, Scheltens P et al. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol 2008; 255: 1302–1308.
5 Brickman AM, Zadorne LB, Guzman VA et al. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer’s disease incidence. Neurobiol Aging 2015; 36: 27–52.
6 Hirao K, Yamashita F, Tsugawa A et al. Association of serum cystatin C with white matter abnormalities in patients with amnestic mild cognitive impairment. Geriatr Gerontol Int 2019; 19: 1036–1040.
7 Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238–1248.
8 Hirao K, Ohnishi T, Hirata Y et al. The prediction of rapid conversion to Alzheimer’s disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005; 28: 1014–1021.
9 Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270–279.
10 Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging.AJR Am J Roentgenol 1987; 149: 351–356.
11 Gerring DT, Nabavi A, Kikinis R et al. An integrated visualization system for surgical planning and guidance using image fusion and an open MR. J Magn Reson 2001; 13: 967–975.
12 Park K, Nemoto K, Yamakawa Y et al. Cerebral white matter hyperintensity as a healthcare quotient. J Clin Med 2019; 8(11): 1823.
13 Yarceanu M, Xie SX, Kling MA et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012; 135 (Pt 12): 3749–3756.
14 Fernando MS, Simpson JE, Matthews F et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006; 37: 1391–1398.
15 Montagne A, Zhao Z, Zlokovic BV. Alzheimer’s disease: a matter of blood-brain barrier dysfunction? J Exp Med 2017; 214: 3151–3169.
16 Behl P, Bocci C, Swartz RH et al. Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch Neurol 2007; 64: 266–272.
17 Bohnen NI, Bogan CW, Muller ML. Frontal and periventricular brain white matter lesions and cortical deafferentation of cholinergic and other neuromodulatory axonal projections. Eur Neurol 2009; 1: 33–50.
18 Bangen KJ, Thomas KR, Weigand AJ et al. Pattern of regional white matter hyperintensity volume in mild cognitive impairment subtypes and associations with decline in daily functioning. Neurobiol Aging 2020; 86: 134–142.
19 Umegae N, Nagai A, Terashima M et al. Cystatin C expression in ischemic white matter lesions. Acta Neurol Scand 2008; 118: 60–67.
20 Levy E, Sastre M, Kumar A et al. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 2001; 60: 94–104.
21 Sun B, Zhou Y, Halabisky B et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer’s disease. Neurobiol Aging 2008; 30: 247–257.
22 Wasserwaar TM, Yaffe K, van der Werf YD, Sexton CE. Associations between modifiable risk factors and white matter of the aging brain: insights from diffusion tensor imaging studies. Neurobiol Aging 2019; 80: 56–70.
23 Jongen C, van der Grond J, Kappelle LJ, Biessels GJ, Viergever MA, Pluim JP. Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia 2007; 50: 1509–1516.
24 Saczynska JS, Sigurdsson S, Jonsson PV et al. Glycemic status and brain injury in older individuals: the age gene/environment susceptibility–Reykjavik study. Diabetes Care 2009; 32: 1608–1613.
25 Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64–74.
26 Manschot SM, Brands AM, van der Grond J et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006; 55: 1106–1115.
27 Reijmer YD, van den Berg E, de Bresser J et al. Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors. Diabetes Metab Res Rev 2011; 27: 195–202.
28 Biessels GJ, Whitmer RA. Cognitive dysfunction in diabetes: how to implement emerging guidelines. Diabetologia 2020; 63: 3–9.
29 Sato T, Hanyu H, Hirose H, Hirakata K, Iwamoto T. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011; 32: 1626–1633.
30 Ogawa Y, Shimmizu S, Takenoshita N, Kaneko Y, Satoto T, Hanyu H. Ambulatory glucose profile in diabetes-related dementia. Geriatr Gerontol Int 2019; 19: 282–286.

How to cite this article: Hirao K, Yamashita F, Sakurai S, et al. Association of regional white matter hyperintensity volumes with cognitive dysfunction and vascular risk factors in patients with amnestic mild cognitive impairment. Geriatr. Gerontol. Int. 2021;1–7. https://doi.org/10.1111/ggi.14211